These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22947131)

  • 1. In vitro tests for aerosol deposition II: IVIVCs for different dry powder inhalers in normal adults.
    Delvadia R; Hindle M; Longest PW; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):138-44. PubMed ID: 22947131
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
    [No Abstract]   [Full Text] [Related]  

  • 3. An Exploration of Factors Affecting
    Ruzycki CA; Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
    Delvadia RR; Longest PW; Hindle M; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro tests for aerosol deposition. I: Scaling a physical model of the upper airways to predict drug deposition variation in normal humans.
    Delvadia RR; Longest PW; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2012 Feb; 25(1):32-40. PubMed ID: 22070526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
    Mohan M; Lee S; Guo C; Peri SP; Doub WH
    AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
    Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of powder residence time for the aerosol delivery performance of a commercial dry powder inhaler Aerolizer(®).
    Jiang L; Tang Y; Zhang H; Lu X; Chen X; Zhu J
    J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):265-79. PubMed ID: 22280548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
    Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
    NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
    Lähelmä S; Kirjavainen M; Kela M; Herttuainen J; Vahteristo M; Silvasti M; Ranki-Pesonen M
    Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
    Olsson B; Borgström L; Lundbäck H; Svensson M
    J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates.
    Yoshida H; Kuwana A; Shibata H; Izutsu KI; Goda Y
    AAPS PharmSciTech; 2017 Apr; 18(3):646-653. PubMed ID: 27173989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.
    Leung SS; Tang P; Zhou QT; Tong Z; Leung C; Decharaksa J; Yang R; Chan HK
    AAPS J; 2015 Nov; 17(6):1407-16. PubMed ID: 26201967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data.
    Tian G; Hindle M; Lee S; Longest PW
    Pharm Res; 2015 Oct; 32(10):3170-87. PubMed ID: 25944585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the performance of two dry powder inhalers in preschool children using an idealized pediatric upper airway model.
    Below A; Bickmann D; Breitkreutz J
    Int J Pharm; 2013 Feb; 444(1-2):169-74. PubMed ID: 23333708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
    Lipworth BJ; Clark DJ
    Pulm Pharmacol Ther; 1997 Aug; 10(4):211-4. PubMed ID: 9695144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers.
    Tavernini S; Farina DJ; Martin AR; Finlay WH
    Pharm Res; 2021 Sep; 38(9):1601-1613. PubMed ID: 34463937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary drug delivery by powder aerosols.
    Yang MY; Chan JG; Chan HK
    J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.